|
Division of
Hematology Oncology
(link)
Archambeault S, Flores NJ, Yoshimi A, Kratz CP,
Reising M, Fischer A, Noellke P, Locatelli F, Sedlacek P, Flotho
C, Zecca M, Emanuel PD,
Castleberry RP, Niemeyer CM, Bader P, Loh ML. Development of an
allele-specific minimal residual disease assay for patients with
juvenile myelomonocytic leukemia.
Blood. 2008 Feb 1;111(3):1124-7. Epub 2007 Nov 13.
Balamurugan A, Lucy I, Reeve G, Mehta P,
Bates JH. Incidence of female breast cancer in Arkansas: are we
following the national trend? J Ark Med Soc. 2009
Jun;105(12):283-4, 286.
Barlogie
B, Anaissie E, van RF, Haessler J,
Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin
A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty
N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J,
Shaughnessy JD. Incorporating bortezomib into upfront treatment
for multiple myeloma: early results of total therapy 3. Br J
Haematol 2007 Jul; 138(2):176 - 185.
Barlogie
B, Anaissie E. Haessler J, van RF, Pineda-Roman M,
Hollmig K, Alsayed Y,
Epstein J, Shaughnessy JD, Crowley J. Complete remission
sustained 3 years from treatment initiation is a powerful
surrogate for extended survival in multiple myeloma. Cancer 2008
Jul 15 113 (2): 355 - 359.
Barlogie
B, Pineda-Roman M, van RF, Haessler J, Anaissie E,
Hollmig K, Alsayed Y, Waheed
S, Petty N, Epstein J, Shaughnessy JD, Tricot G, Zangari M,
Zeldis J, Barer S, Crowley J. Thalidomide arm of Total Therapy 2
improves complete remission duration and survival in myeloma
patients with metaphase cytogenetic abnormalities. Blood 2008
Oct 15 112 (8): 3115 - 3121.
Barlogie
B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van RF,
Fassas A, Zangari M, Hollmig K,
Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna
S, Fox M, Crowley J. Thalidomide and hematopoietic-cell
transplantation for multiple myeloma. N Engl J Med 2006 Mar;
354(10):1021 - 1030.
Barlogie
B, Tricot G, Haessler J, van RF, Cottler-Fox M, Anaissie E,
Waldron J, Pineda-Roman M, Thertulien R, Zangari M,
Hollmig K, Mohiuddin A,
Alsayed Y, Hoering A, Crowley J, Sawyer J. Cytogenetically
defined myelodysplasia after melphalan-based autotransplantation
for multiple myeloma linked to poor hematopoietic stem-cell
mobilization: the Arkansas experience in more than 3,000
patients treated since 1989. Blood 2008 Jan; 111(1):94 - 100.
Barlogie
B, Tricot G, Rasmussen E, Anaissie E, van RF, Zangari M, Fassas
A, Hollmig K, Pineda-Roman
M, Shaughnessy J, Epstein J, Crowley J. Total therapy 2 without
thalidomide in comparison with total therapy 1: role of
intensified induction and posttransplantation consolidation
therapies. Blood 2006 Apr; 107(7):2633 - 2638.
Barlogie
B, van RF, Shaughnessy JD, Epstein J, Yaccoby S, Pineda-Roman M,
Hollmig K, Alsayed Y,
Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS,
Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven-year median
time to progression with thalidomide for smoldering myeloma:
partial response identifies subset requiring earlier salvage
therapy for symptomatic disease. Blood 2008 Oct 15 112 (8): 3122
- 3125.
Barlogie
B, Zangari M, Bolejack V, Hollmig K,
Anaissie E, van RF, Pineda-Roman M, Mohiuddin A, Crowley J,
Tricot G. Superior 12-year survival after at least 4-year
continuous remission with tandem transplantations for multiple
myeloma. Clin Lymphoma Myeloma 2006 May; 6(6):469 - 474.
Choi H, Jackson NL, Shaw DR,
Emanuel PD, Liu YL, Tousson A,
Meng Z, Blume SW. mrtl-A translation/localization regulatory
protein encoded within the human c-myc locus and distributed
throughout the endoplasmic and nucleoplasmic reticular network.
J Cell Biochem 2008 Nov 1;105(4):1092-108.
Choi JY,
Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis
W, Rae JM, Yeh IT, Hutchins LF,
Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF,
Ambrosone CB. Nitric oxide synthase variants and disease-free
survival among treated and untreated breast cancer patients in a
Southwest Oncology Group clinical trial. Clin Cancer Res. 2009
Aug 15;15(16):5258-66. Epub 2009 Aug 11.
Divekar
RD, Mehta P, El-Serag HB,
Raval GG, Tancinco E, Raval P, Taddei T, Monto A, Kohlwes J.
Managing Advanced Hepatocellular Carcinoma. Fed Pract.
2009;26(suppl 1):1–24B.
Eid A,
Petty M, Hutchins L,
Thompson R. 'Breaking bad news': standardized patient
intervention improves communication skills for
hematology-oncology fellows and advanced practice nurses. J
Cancer Educ 2009 24 (2): 154 - 159.
Emanuel P;
Mixed Myeloproliferative and Myelodysplastic Disorders.
Current Hematologic Malignancy Reports 2007 2 9‑12.
Emanuel PD. Juvenile
myelomonocytic leukemia and chronic myelomonocytic leukemia.
Leukemia 2008 June 12(22):1335-1342.
Emanuel PD. RAS pathway
mutations in juvenile myelomonocytic leukemia.
Acta Haematol
2008;119(4):207-11. Epub 2008 Jun 20.
Ganz PA,
Hussey MA, Moinpour CM, Unger JM,
Hutchins LF,
Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Late
cardiac effects of adjuvant chemotherapy in breast cancer
survivors treated on Southwest Oncology Group protocol s8897.J Clin Oncol
2008 Mar 10;26(8):1223-30. Epub 2008 Jan 28.
Gentry RW, Mehta J,
Safar M, Kyasa MJ, Thompson
R, Hester DM, Mehta P.
Disclosing prognosis when patients don’t ask. Fed Pract
2006;23(4):14-16, 33.
Gentry R, Mehta J, Hester M,
Thompson R, Mehta P. When is
the best time to refer to hospice? Federal Practitioner
2007; 11: 51-53.
Gerena-Lewis M, Crawford J, Bonomi P,
Maddox AM, Hainsworth J,
McCune DE, Shukla R, Zeigler H, Hurtubise P, Chowdhury TR,
Fletcher B, Dyehouse K, Ghalie R, Jazieh AR. A Phase II Trial of
Denileukin Diftitox in Patients With Previously Treated Advanced
Non-Small Cell Lung Cancer. Am J Clin Oncol 2009 May 8 [Epub
ahead of print].
Greene
P, Mays G, Kim K, Hagar B, Goldsmith G, Bursac Z, Carter D, Duke
K, Mehta P, Henry-Tillman R.
Colorectal cancer screening in Arkansas: Implications for cancer
prevention in primary care. J Ark Med Soc 2009.
Gonzalez R,
Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of
Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006;16(6):521-6.
Govindarajan R,
Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI.
Reversible posterior
leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY
43-9006. J Clin Oncol 2006; 24(28):e48.
Govindarajan
R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L,
Kim PJ, Owens RJ, Lang NP. Thiazolidinediones and the risk of
lung, prostate, and colon cancer in patients with diabetes.
J Clin Oncol 2007; 25(12):1476-81.
Govindarajan
R, Young JW, Harless CL, Hutchins, LF. Barriers to clinical
trials vary according to the type of trial and the institution.
J Clin Oncol 2007; 25 (12):1633-4; 1634.
Guo L,
Lobenhofer EK, Wang C, Shippy R, Harris SC, Zhang L, Mei N, Chen
T, Herman D, Goodsaid FM,
Hurban P, Phillips KL, Xu J, Deng X, Sun YA, Tong W, Dragan YP,
Shi L. Rat toxicogenomic study reveals analytical consistency
across microarray platforms. Nat Biotechnol 2006 Sep 24 (9):
1162 - 1169.
Haessler
J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van RF,
Anaissie E, Pineda-Roman M, Zangari M,
Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot
G, Barlogie B. Benefit of complete response in multiple myeloma
limited to high-risk subgroup identified by gene expression
profiling. Clin Cancer Res 2007 Dec; 13(23):7073 - 7079.
Hanamura
I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR,
Hollmig K, Zangarri M,
Pineda-Roman M, van RF, Cavallo F, Burington B, Crowley J,
Tricot G, Barlogie B, Shaughnessy JD. Frequent gain of
chromosome band 1q21 in plasma-cell dyscrasias detected by
fluorescence in situ hybridization: incidence increases from
MGUS to relapsed myeloma and is related to prognosis and disease
progression following tandem stem-cell transplantation. Blood
2006 Sep; 108(5):1724 - 1732.
Harrington SE,
Smith TJ. The role of chemotherapy at the end of life: "when is
enough, enough?". JAMA. 2008 Jun 11;299(22):2667-78.
Henry-Tillman R, Mehta P.
Breaking down barriers to colorectal cancer screening. Fed
Pract 2008;25(7):14, 16.
Herman D,
Ong TT, Usaj G,
Mathur H, Baranger HU. Level Spacings in Random Matrix Theory
and Coulomb Blockade Peaks in Quantum Dots. Phys. Rev.
2007:195448.
Hershman
DL, Unger JM, Barlow WE, Hutchins LF,
Martino S, Osborne CK, Livingston RB, Albain KS. Treatment
quality and outcomes of African American versus white breast
cancer patients: retrospective analysis of Southwest Oncology
studies S8814/S8897. J Clin Oncol 2009 May 1 27 (13): 2157 -
2162.
Hesketh
PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B,
Krentzin M, Nowd P, Arnaoutakis K,
Hesketh AM. Aprepitant as salvage antiemetic therapy in breast
cancer patients receiving doxorubicin and cyclophosphamide.
Support Care Cancer. 2008 Dec 6. [Epub ahead of print]
Hoering
A, Crowley J, Shaughnessy JD, Hollmig K,
Alsayed Y, Szymonifka J, Waheed S, Nair B, van RF, Anaissie E,
Barlogie B. Complete remission in multiple myeloma examined as
time-dependent variable in terms of both onset and duration in
total therapy protocols. Blood. 2009 Aug 13;114(7):1299-305.
Epub 2009 Jun 10.
Hutchins LF,
Moon J, Clark JI, Thompson JA, Lange MK, Flaherty LE, Sondak
VK. Evaluation of interferon alpha-2B and thalidomide in
patients with disseminated malignant melanoma, phase 2, SWOG
0026.Cancer. 2007 Nov 15;110(10):2269-75.
Hutchins LF, Editor-in-Chief; Douglas W. Blayney,
Judith S. Ochs, Jennifer E. Schwartz, Associate Editors.
Achieving Career Success in Oncology. Alexandria, VA:
ASCO - American Society of Clinical Oncology; 2008. 308 p.
Hutchins LF,
Editor-in-Chief; Douglas W. Blayney, Judith S. Ochs,
Jennifer E. Schwartz, Associate Editors. Achieving Career
Success in Oncology. Alexandria, VA:ASCO – American
Scoiety of Clinical Oncology; 2008. 308 p.
Joseph J, Rimawi A,
Mehta P, Cottler-Fox M,
Sinha A, Singh BK, Pacheco R, Smith ES 3rd, Mehta JL. Safety
and effectiveness of granulocyte-colony stimulating factor
in mobilizing stem cells and improving cytokine profile in
advanced chronic heart failure. Am J Cardiol 2006 Mar
1;97(5):681-4. Epub 2006 Jan 6.
Kapoor P,
Singh E, Radhakrishnan P, Mehta P. Splenectomy in plasma cell
dyscrasias: a review of clinical practice. Am J Hematol 2006; 81: 945-54.
Keshava-Prasad H,
Hester DM, Mehta J, Mehta P.
Informed consent in medical oncology. Fed Pract
2008;25(7):26, 29-31, 35.
Khatcheressian J, Harrington SB,
Lyckholm LJ, Smith TJ. 'Futile care': what to do when your
patient insists on chemotherapy that likely won't help. Oncology
(Williston Park). 2008 Jul 22(8):881-8; discussion 893, 896,
898. Comment in Oncology (Williston Park) 2008 Oct
22(11):1206.
Kyasa MJ.,
Breau RL., Hanna E., Suen JY., Maddox
AM. Gemcitabine and Cisplatin in Patients With
Locally Advanced, Recurrent, or Metastatic Head and Neck Cancer:
Results of a Phase II Trial. Journal of Applied Research
2008 Vol. 8(No. 1):43-47.
Linden HM, Haskell CM, Green SJ,
Osborne CK, Sledge GW Jr, Shapiro CL, Ingle JN, Lew D,
Hutchins
LF, Livingston RB, Martino S. Sequenced compared with
simultaneous anthracycline and cyclophosphamide in high-risk
stage I and II breast cancer: final analysis from INT-0137
(S9313). J Clin Oncol 2007; 25(6):656-61.
Liu YL.,
Castleberry RP., Emanuel PD.
PTEN deficiency is a common defect in juvenile myelomonocytic
leukemia. Leuk Res 2009 May; 33(5):671 - 677.
Liu YL.,
Castleberry RP., Emanuel PD.
Author’s response to the comments on “PTEN deficiency is a
common defect in juvenile myelomonocytic leukemia.” Leuk Res
2009 Jun 4.
Loh ML, Sakai
DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG,
Chen L, Bergstraesser E, Bueso-Ramos CE,
Emanuel PD, Hasle H, Issa JP, van den
Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M,
Zecca M, Shannon KM, Niemeyer CM. Mutations in CBL occur
frequently in juvenile myelomonocytic leukemia. Blood. 2009 Jul
1. [Epub ahead of print]
Makhoul I,
Claxton D, Rybka W. Pure B-Cell Disorders. eMedicine, eMedicine
Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery:
Hematology [Internet]. Aug 25, 2006. Available from:
http://www.emedicine.com/med/topic216.htm.
Makhoul I,
Harvey H, Makhoul H, Souba W. Breast cancer. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and
Surgery: Oncology [Internet].Sep20, 2006.
http://www.emedicine.com/med/topic2808.htm.
Makhoul I, Javeed M, Ballard J. Spur Cell Anemia. eMedicine, eMedicine
Specialites: Medicine, OB/Gyn, Psychiatry, and Surgery:
Hematology [Internet]. Aug 25, 2006. Available from:
http://www.emedicine.com/med/topic2163.htm.
Mamounas
EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A,
Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG,
Kroener JF, Hutchins LF,
Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP,
Wolmark N. Benefit from exemestane as extended adjuvant therapy
after 5 years of adjuvant tamoxifen: intention-to-treat analysis
of the National Surgical Adjuvant Breast And Bowel Project B-33
trial.J Clin Oncol. 2008 Apr 20;26(12):1965-71. Epub 2008 Mar
10.
Mansoor M,
Ryan CJ, Makhoul I, Sachdeva K, Curti B. Germ Cell Tumors. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry,
and Surgery: Oncology[Internet]. July 27, 2006.
http://www.emedicine.com/med/topic863.htm.
Mehta P.
Poems on Cancer Education. J Cancer Educ 2006; 21(2):108-9.
Mehta P.
Chemotherapy induced neutropenia in the new millennium. Federal
Practitioner 2006; 23 (supplement 2) 2-3.
Mehta P.
He didn't have a chance. J Clin Oncol 2007 Aug
1;25(22):3378-9.
Mehta P.
Special Treatment: A commentary on "When Two Worlds Collide."
J Clin Oncology 2007; 25: 4018-9.
Mehta P,
Hester M, Safar AM, Thompson
R. Ethics-in-oncology forums. J Cancer Educ 2007
Fall;22(3):159-64.
Mehta P,
Nair B. TNF alpha inhibition and AML. Am J Hematol 2007
Dec 27; [Epub ahead of print]
Mehta P;Holtan
SG; Knowing too much. J Cancer Educ 2008 23 (2): 133 -
134.
Mehta P, Henry-Tillman R.
Obesity-related cancer: an emerging need for more education.
J Cancer Educ 2008;23(4):201-3.
Mehta P,
Henry-Tillman R. Guest Editorial: Colorectal cancer screening in
the VA. Fed Pract 2008 July.
Mehta P,
Lyckholm L. Point/Counterpoint: Is burnout a well recognized
issue among physicians? HemOncToday 2008 6:11.
Meng
Z, Jackson NL, Choi H, King PH, Emanuel
PD, Blume SW. Alterations in RNA-binding activities
of IRES-regulatory proteins as a mechanism for physiological
variability and pathological dysregulation of IGF-IR
translational control in human breast tumor cells.
J Cell Physiol 2008 Oct;217(1):172-83.
Midathada M,
Mehta J, Govindarajan R, Safar AM, Hester DM,
Kyasa MJ,
Mehta P.
When substance abuse interferes with cancer treatment. Federal
Practitioner 2006; 23 (9): 39-51.
Monzavi-Karbassi B, Hennings LJ,
Artaud C, Liu T, Jousheghany F, Pashov A, Murali R,
Hutchins LF, Kieber-Emmons T. Preclinical studies of carbohydrate mimetic
peptide vaccines for breast cancer and melanoma. Vaccine 2007;
25(16):3022-31.
Nair B,
Mehta P. Reviews of “Bone Marrow and Stem Cell
Transplantation” and “Renewing the Stuff of Life: Stem Cells,
Ethics and Public Policy,” JAMA 2007; 298: 1571.
Nair B, Raval G,
Mehta P. TNF-alpha inhibitor
etanercept and hematologic malignancies: report of a case and
review of the literature. Am J Hematol 2007
Nov;82(11):1022-4.
Nair B,
Safar A, Garrison W, Sherman A, Mehta P.
Smoking cessation among patients in a cancer clinic: evaluation
of a novel, motivational stop-smoking pocket calendar. J Cancer
Educ. 2009;24(3):210-1.
Nair B,
Shaughnessy JD, Zhou Y, strid-Cartron M, Qu P, van RF, Anaissie
E, Alsayed Y, Waheed S, Hollmig K,
Szymonifka J, Petty N, Hoering A, Barlogie B. Gene expression
profiling of plasma cells at myeloma relapse from total therapy
2 predicts subsequent survival. Blood. 2009 Jun
25;113(26):6572-5. Epub 2009 Apr 23.
Norris LB
and Mehta P. The role of granulocyte growth factors.
Federal
Practitioner 2006; 23 (supplement 2) 16-25.
O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP,
Emanuel PD,
Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP,
Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman
MS, Talpaz M, Wetzler M; Chronic myelogenous leukemia. J Natl
Compr Canc Netw 2007 May 5 (5): 474 ‑ 496.
Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van RF,
Zangari M, Walker R, Hollmig K,
Shaughnessy JD, Epstein J, Krishna S, Crowley J, Barlogie B.
Complete response in myeloma extends survival without, but not
with history of prior monoclonal gammopathy of undetermined
significance or smouldering disease. Br J Haematol 2007 Feb;
136(3):393 - 399.
Prasad HK,
Govindarajan R. Heparin-induced skin necrosis
associated with thrombocytopenia and acquired protein C and
protein S deficiency. Am J Hematol 2007
Dec;82(12):1116-7.
Prasad HK, Kaushal V,
Mehta P. Isolated
thrombocytopenia induced by thalidomide in a patient with
multiple myeloma: case report and review of literature. Am J
Hematol 2007 Sep;82(9):855-7.
Raval GG, Wingard JR,
Mehta
P. Bone Marrow Transplantation, Long-Term Effects. eMedicine,
eMedicine Specialties: Pediatric: Oncology [Internet]. July 31,
2006.
http://www.emedicine.com/ped/topic2551.htm.
Raza
A;Galili N;Callander N;Ochoa L;Piro L;Emanuel
P;Williams S;Burris H;Faderl S;Estrov Z;Curtin
P;Larson RA;Keck JG;Jones M;Meng L;Brown GL; Phase 1-2a
multicenter dose-escalation study of ezatiostat hydrochloride
liposomes for injection (Telintra(R), TLK199), a novel
glutathione analog prodrug in patients with myelodysplastic
syndrome. J Hematol Oncol 2009 2 20.
Regan
MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming
GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M,
Coates AS, Goldhirsch A, Gelber RD, SOFT/TEXT/PERCHE Steering
Committee., International Breast Cancer
Study Group. Premenopausal endocrine-responsive early
breast cancer: who receives chemotherapy?. Ann Oncol 2008 Jul;
19(7):1231-41.
Safar AM,
O'Sullivan P, Ray L, Hutchins L, Mehta P. Editorial clubs as a
new teaching tool in postgraduate training. J Cancer Educ 2006; 21(3):163-5.
Safar AM,
Spencer H, Su X, Cooney CA, Shwaiki A and Fan C-Y. Promoter
hypermethylation for molecular nodal staging in non–small cell
lung cancer. Arch Pathol Lab Med 2007; 131(6):936-941.
Shaughnessy JD, Haessler J, van RF, Anaissie E, Pineda-Roman M,
Cottler-Fox M, Hollmig K,
Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J,
Crowley J, Barlogie B. Testing standard and genetic parameters
in 220 patients with multiple myeloma with complete data sets:
superiority of molecular genetics. Br J Haematol 2007 Jun;
137(6):530 - 536.
Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura
I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu
H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M,
Hollmig K, Mohiuddin A,
Pineda-Roman M, Tricot G, van RF, Sawyer J, Alsayed Y, Walker R,
Zangari M, Crowley J, Barlogie B. A validated gene expression
model of high-risk multiple myeloma is defined by deregulated
expression of genes mapping to chromosome 1. Blood 2007 Mar;
109(6):2276 - 2284.
Sherman AC, Edwards D, Simonton S,
Mehta P. Caregiver stress
and burnout in an oncology unit. Palliat Support Care
2006 Mar;4(1):65-80.
Shi L,
Jones WD, Jensen RV, Harris SC, Perkins RG, Goodsaid FM, Guo L,
Croner LJ, Boysen C, Fang H, Qian F, Amur S, Bao W, Barbacioru
CC, Bertholet V, Cao XM, Chu TM, Collins PJ, Fan XH, Frueh FW,
Fuscoe JC, Guo X, Han J, Herman D,
et al. The balance of reproducibility, sensitivity, and
specificity of lists of differentially expressed genes in
microarray studies. BMC Bioinformatics 2008 9 Suppl 9 S10.
Shi L,
Jones WD, Jensen RV, Wolfinger RD, Kawasaki ES,
Herman D, Guo L, Goodsaid
FM, Tong W. Reply to statistical methods and microarray data.
Nat Biotechnol 2007 25 (1):26-27.
Shi L,
Jones WD, Jensen RV, Wolfinger RD, Kawasaki ES,
Herman D, Guo L, Goodsaid
FM, Tong W. Reply to MAQC papers over the cracks. Nat Biotechnol.
2007 (25 (1)):28-29.
Shi L,
Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ,
de LF, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC,
Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW,
Goodsaid FM, Herman D, et
al. The MicroArray Quality Control (MAQC) project shows inter-
and intraplatform reproducibility of gene expression
measurements. Nat Biotechnol 2006 Sep 24 (9): 1151 - 1161.
Shippy
R, Fulmer-Smentek S, Jensen RV, Jones WD, Wolber PK, Johnson CD,
Pine PS, Boysen C, Guo X, Chudin E, Sun YA, Willey JC, Thierry-Mieg
J, Thierry-Mieg D, Setterquist RA, Wilson M, Lucas AB,
Novoradovskaya N, Papallo A, Turpaz Y, Baker SC, Warrington JA,
Shi L, Herman D. Using RNA
sample titrations to assess microarray platform performance and
normalization techniques. Nat Biotechnol 2006 Sep 24 (9): 1123 -
1131.
Sibley
A, Maddox AM.
Myelodysplasia and copper deficiency induced by
denture paste.
Am J Hematol. 2009 Jun 11. [Epub ahead of print]
Suva L,
Griffin R, Makhoul I.
Mechanisms of bone metastases of breast cancer.
Endocr Relat Cancer. 2009 May 14. [Epub ahead of print]
Swetz
KM, Harrington SE, Matsuyama
RK, Shanafelt TD, Lyckholm LJ. Strategies for Avoiding Burnout
in Hospice and Palliative Medicine: Peer Advice for Physicians
on Achieving Longevity and Fulfillment. J Palliat Med. 2009 Jul
21. [Epub ahead of print]
Unger JM, Coltman CA Jr., Drowley JJ,
Hutchins LF, Martino S,
Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED,
Albain KS. Impact of the year 2000 Medicare policy change on
older patient enrollment to cancer clinical trials. J Clin
Oncol 2006 Jan 1;24(1):141-4.
van RF,
Bolejack V, Hollmig K,
Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari
M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J,
Barlogie B. High serum-free light chain levels and their rapid
reduction in response to therapy define an aggressive multiple
myeloma subtype with poor prognosis. Blood 2007 Aug; 110(3):827
- 832.
Walker
R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD,
Epstein J, van HR, Erdem E, Hoering A, Crowley J, Ferris E,
Hollmig K, van RF, Zangari
M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ.
Magnetic resonance imaging in multiple myeloma: diagnostic and
clinical implications. J Clin Oncol 2007 Mar; 25(9):1121 - 1128.
Wang-Gillam A. Siegel E, Mayes D,
Hutchins L,
Zhou YH. Anti-tumor effect of doxycycline on gioblastoma
cells. J Cancer Molecules 2007 November
5;3(5)147-153.
Wang-Gillam
A, Miles DA,
Hutchins LF.
Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates.
Oncologist. 2008 Jul;13(7):821-7. Epub 2008 Jul
9.
Wang-Gillam
A;Valentine J;Sherman AC; Mehta P;
Experiences of Institutional Review Board (IRB) and Protocol
Review and Monitoring Committee (PRMC) Rotations in
Hematology/Oncology Training. J Cancer Educ 2008 23 (2):
71 - 73.
Yanni
LM, Priestley JW, Schlesinger JB, Ketchum JM, Johnson BA,
Harrington SE. Development
of a comprehensive e-learning resource in pain management. Pain
Med 2009 Jan 10 (1): 95 - 105.
Yanni
LM, Weaver MF, Johnson BA, Morgan LA,
Harrington SE, Ketchum JM. Management of chronic
nonmalignant pain: a needs assessment in an internal medicine
resident continuity clinic. J Opioid Manag 2008 Jul 4 (4): 201 -
211.
Zhan F,
Barlogie B, Arzoumanian V, Huang Y, Williams DR,
Hollmig K, Pineda-Roman M,
Tricot G, van RF, Zangari M, Dhodapkar M, Shaughnessy JD.
Gene-expression signature of benign monoclonal gammopathy
evident in multiple myeloma is linked to good prognosis. Blood
2007 Feb; 109(4):1692 - 1700.
Zhan F,
Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J,
Yaccoby S, Sawyer J, Burington B, Anaissie E,
Hollmig K, Pineda-Roman M,
Tricot G, van RF, Walker R, Zangari M, Crowley J, Barlogie B,
Shaughnessy JD. The molecular classification of multiple myeloma.
Blood 2006 Sep; 108(6):2020 - 2028.
|